Lonza Group AG (OTCMKTS:LZAGY – Get Free Report) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 200 shares, a decline of 98.9% from the November 15th total of 18,600 shares. Based on an average daily trading volume, of 286,800 shares, the short-interest ratio is currently 0.0 days.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on LZAGY. Redburn Atlantic raised Lonza Group to a “strong-buy” rating in a research report on Wednesday, November 27th. The Goldman Sachs Group raised Lonza Group to a “strong-buy” rating in a report on Wednesday, October 9th.
Check Out Our Latest Research Report on Lonza Group
Lonza Group Price Performance
About Lonza Group
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.
Read More
- Five stocks we like better than Lonza Group
- What is the Nasdaq? Complete Overview with History
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- 5 Top Rated Dividend Stocks to Consider
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.